Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Massachusetts: - Beverly Hospital — Beverly, Massachusetts
- Boston Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Lahey Hospital and Medical Center — Burlington, Massachusetts
- Addison Gilbert Hospital — Gloucester, Massachusetts
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Massachusetts: - Beverly Hospital — Beverly, Massachusetts
- Tufts Medical Center — Boston, Massachusetts
- Lahey Clinic — Burlington, Massachusetts
- Addison Gilbert Hospital — Gloucester, Massachusetts
- Lowell General Hospital — Lowell, Massachusetts
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Massachusetts: - Research Site — Boston, Massachusetts
- Research Site — Worcester, Massachusetts
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Massachusetts: - Research Site — Boston, Massachusetts
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Massachusetts: - Tufts Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Massachusetts: - Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber at St. Elizabeth's Medical Center — Brighton, Massachusetts
- Lahey Clinic — Burlington, Massachusetts
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Massachusetts: - Tufts Medical Center — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
- DFCI @ Foxborough — Foxborough, Massachusetts
- DFCI @ Milford Regional Hospital — Milford, Massachusetts
- DF/BWCC in Clinical Affiliation with South Shore Hospital — South Weymouth, Massachusetts
Phase 1, Phase 2 Recruiting Industry
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…
Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Tubulis GmbH
NCT ID: NCT06657222
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in Massachusetts: - Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04434040
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advance…
Sponsor: Ellipses Pharma
NCT ID: NCT05573126
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in P…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT06827613
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (com…
Sponsor: Massachusetts General Hospital
NCT ID: NCT04230109
Sites in Massachusetts: - Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Massachusetts General Hospital - North Shore Cancer Center — Danvers, Massachusetts
- Massachusetts General Hospital at Newton-Wellesley Hospital — Newton, Massachusetts
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (…
Sponsor: Filipa Lynce, MD
NCT ID: NCT05795101
Sites in Massachusetts: - Brigham and Women's Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts